EUCTR2020-004848-29-IT进行中（未招募）1 期
A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´sdisease (EVOKE) - EVOKE
OVO NORDISK. S.P.A.0 个研究点目标入组 1,840 人开始时间: 2021年6月8日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,840
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male or female, aged 55-85 years (both inclusive) at the time of signing informed consent.
- •- MCI or mild dementia of the Alzheimer's type according to the National Institute of Aging-Alzheimer's Association (NIA-AA) 2018 criteria.
- •- Clinical Dementia Rating (CDR) global score of 0.5 and CDR of 0.5 or more in at least one of the three instrumental activities of daily living categories (personal care, home & hobbies, community affairs) Or CDR global score of 1.0
- •- Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) delayed memory index score of less than or equal to 85
- •- Mini-Mental State Examination (MMSE) greater than or equal to 22.
- •- Amyloid positivity established with either amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) Aß1-42.
- •- If receiving an approved Alzheimer's disease treatment (such as acetylcholinesterase inhibitors or memantine) the dose must have been stable for at least 3 months prior to screening and should not be changed during the trial unless medically necessary
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 276
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1564
排除标准
- •- Brain magnetic resonance imaging (MRI) (or computerised tomography (CT)) scan suggestive of clinically significant structural central nervous system (CNS) disease confirmed by central read (e.g. cerebral largevessel disease [large vessel (cortical) infarcts greater than 10 mm in diameter], prior macro-haemorrhage [ greater than 1 cm^3], cerebral vascular malformations, cortical hemosiderosis, intracranial aneurism(s), intracranial tumours, changes suggestive of normal pressure hydrocephalus).
- •- Brain MRI (or CT) scan suggestive of significant small vessel pathology confirmed by central read and defined as greater than 1 lacunar infarct and/or age-related white matter changes (ARWMC) greater than 2,(white matter (WM) greater than 20 mm).
- •- Brain MRI (or CT) scan suggestive of strategic infarcts defined as bilateral thalamic lacunar infarcts and singular paramedian thalamic infarcts confirmed by central read.
- •- Evidence of a relevant neurological disorder other than mild cognitive impairment (MCI) or mild dementia of the Alzheimer's type at screening, including but not limited to Parkinson's disease, Lewy body disease, frontotemporal dementia of any type, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, systemic lupus erythematosus, progressive supranuclear palsy, neurosyphilis, human immunodeficiency virus (HIV), learning disability, intellectual disability, hypoxic cerebral damage, or significant head trauma with loss of consciousness that led to persistent cognitive deficits.
- •- Evidence of a clinically relevant or unstable psychiatric disorder, based on Diagnostic and Statistical Manual of Mental Disorders (DSM–5) criteria, including schizophrenia or other psychotic disorder, or bipolar disorder. A subject with a history of major depression who has not had an episode in the last 24 months before the day of screening and is considered in remission or whose depression is controlled with treatment can be included in the trial per investigator's judgement.
研究者
相似试验
进行中（未招募）
1 期
A research study investigating semaglutide in people with early Alzheimer’s disease (EVOKE plus)Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s typeMedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-004864-25-DEovo Nordisk A/S1,840
进行中（未招募）
1 期
A research study investigating semaglutide in people with early Alzheimer’s disease (EVOKE)Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s typeMedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2020-004848-29-DEovo Nordisk A/S1,840
进行中（未招募）
1 期
A research study investigating semaglutide in people with early Alzheimer’s disease (EVOKE)Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s typeMedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2020-004848-29-BEovo Nordisk A/S1,840
进行中（未招募）
1 期
A research study investigating semaglutide in people with early Alzheimer’s disease (EVOKE plus)Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s typeMedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2020-004864-25-SIovo Nordisk A/S1,840
招募中
3 期
A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer*s disease (EVOKE plus)Alzheimer10012272DementiaNL-OMON51141ovo Nordisk20